<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03790852</url>
  </required_header>
  <id_info>
    <org_study_id>KSI-CL-101</org_study_id>
    <nct_id>NCT03790852</nct_id>
  </id_info>
  <brief_title>Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO</brief_title>
  <official_title>A Phase 1/1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kodiak Sciences Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kodiak Sciences Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety,
      tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5
      mg and 5 mg
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 26, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ocular (study eye) and systemic adverse events</measure>
    <time_frame>Week 72</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Mean change in central retinal thickness on optical coherence tomography</measure>
    <time_frame>Baseline, Week 72</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean change in best corrected visual acuity</measure>
    <time_frame>Baseline, Week 72</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Wet Age-related Macular Degeneration</condition>
  <condition>Retinal Vein Occlusion</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>KSI-301 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KSI-301 2.5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KSI-301 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KSI-301 5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KSI-301</intervention_name>
    <description>Intravitreal injection</description>
    <arm_group_label>KSI-301 2.5 mg</arm_group_label>
    <arm_group_label>KSI-301 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Wet AMD Cohort

          1. Treatment naïve wet age-related macular degeneration involving the fovea.

          2. A lesion area &lt;30 mm2 (12 disc areas) of any lesion type.

          3. BCVA ETDRS letter score ≤ 78 and ≥ 23 (⁓20/25 to ⁓20/320 Snellen equivalent) in the
             study eye.

          4. Decrease in vision in the study eye determined by the investigator to be primarily the
             result of wAMD.

        DME Cohort

          1. Treatment naïve diabetic macular edema.

          2. BCVA ETDRS letter score ≤ 78 and ≥ 23 (⁓20/25 to ⁓20/320 Snellen equivalent) in the
             study eye.

          3. Central subfield thickness (CST) of ≥ 300 microns on SD-OCT (Heidelberg Spectralis or
             equivalent).

          4. Decrease in vision in the study eye determined by the investigator to be primarily the
             result of DME.

        RVO Cohort

          1. Treatment naïve retinal vein occlusion with macular edema and secondary visual
             impairment.

          2. BCVA ETDRS letter score ≤ 78 and ≥ 23 (⁓20/25 to ⁓20/320 Snellen equivalent) in the
             study eye.

          3. Central subfield thickness (CST) of ≥ 300 microns on SD-OCT (Heidelberg Spectralis or
             equivalent).

          4. Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) are
             both eligible.

          5. Decrease in vision in the study eye determined by the investigator to be primarily the
             result of macular edema secondary to RVO.

        General Inclusion Criteria

          -  Adults ≥ 21 years.

        Exclusion Criteria:

        Wet AMD Cohort:

          1. Choroidal neovascularization due to causes other than age-related macular degeneration
             in the study eye.

          2. Geographic atrophy and/or subretinal fibrosis involving the fovea of the study eye.

          3. Prior intravitreal anti-VEGF therapy in the study eye.

        DME Cohort:

          1. Initial diagnosis of DME of more than 6 months from screening in the study eye.

          2. Hard exudates in the fovea.

          3. Prior intravitreal anti-VEGF therapy or steroid injection, or steroid implant
             (dexamethasone or triamcinolone) in the study eye.

          4. Moderate or dense vitreous hemorrhage preventing clear. visualization of the macula or
             optic disc in the study eye.

          5. Fibrovascular proliferation or tractional retinal detachment in the posterior pole in
             the study eye. If traction is present outside the posterior pole, it should be
             considered not at risk of increasing and threatening the macula with the use of
             anti-VEGF injections, in the investigator's judgement.

        RVO Cohort:

          1. Initial diagnosis of RVO of more than 4 months from screening in the study eye.

          2. Active retinal or iris neovascularization in the study eye.

          3. Prior intravitreal anti-VEGF therapy or steroid injection, or steroid implant
             (dexamethasone or triamcinolone) in the study eye.

        For all phase 1b subjects:

          1. Uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment
             with antiglaucoma medication) in the study eye.

          2. History of retinal detachment or treatment or surgery for retinal detachment in the
             study eye.

          3. Any history of uveitis in either eye.

          4. Significant media opacities, including visually significant cataract, in the study eye
             that might interfere with visual acuity assessments, optical coherence tomography,
             fundus photography, or with examination of the eye for assessment of safety.

          5. Prior vitrectomy surgery in the study eye.

          6. Active retinal disease other than the conditions under investigation.

          7. Active ocular or periocular infection or inflammation in either eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <zip>29501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodiak Sciences Investigative Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 27, 2018</study_first_submitted>
  <study_first_submitted_qc>December 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2019</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DME</keyword>
  <keyword>wAMD</keyword>
  <keyword>RVO</keyword>
  <keyword>KSI-301</keyword>
  <keyword>Kodiak</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

